



WEMMH/SB/08A (403)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/705,561
				Filing Date	11/11/2003
				First Named Inventor	David A. WILLIAMS
				Group Art Unit	1633
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	7037-485
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
IKH		6,472,204 B1	10-29-2002	Asada et al	

Examiner Signature	/Kelaginamane Hiriyanna/	Date Considered	03/09/2007
-----------------------	--------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known			
				Application Number	10/705,561		
				Filing Date	11/11/2003		
				First Named Inventor	David A. WILLIAMS		
				Group Art Unit	1633		
				Examiner Name			
Sheet	2	of	3	Attorney Docket Number	7037-485		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite, No.	Foreign Patent Document Country Code- Number-Kind Code ² (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁶
/KH/		WO 97/18318	A1	05-22-1997	Takara Shuzo Co., L		<input type="checkbox"/>

Examiner Signature	/Kelaginamane Hiriyanal/	Date Considered	03/09/2007
-----------------------	--------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/705,561
				Filing Date	11/11/2003
				First Named Inventor	David A. WILLIAMS
				Group Art Unit	1633
				Examiner Name	
				Attorney Docket Number	7037-485
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published			T ²
<div style="display: flex; align-items: center; justify-content: center;"> <div style="writing-mode: vertical-rl; transform: rotate(180deg); font-size: 2em; margin-right: 10px;">↓</div> <div style="font-size: 2em;">V</div> </div>		CAVAZZANA-CALVO, MARINA ET AL., "Gene therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease", Science, 2000, Vol./Issue No. 288, pp. 669-672			<input type="checkbox"/>
		DHAWAN, SUBHASH ET AL., "Increased expression of alpha-4-beta-1 and alpha-5-beta-1 integrins on HTLV-I-infected lymphocytes", Virology, 1993, Vol./Issue No. 197:2, pp. 778-781			<input type="checkbox"/>
		HANANBERG, H. ET AL., "Colocalization of Retrovirus and Target Cells on Specific Fibronectin Fragments Increases Genetic Transduction of Mammalian Cells", Nature Medicine, August 1996, Vol./Issue No. 2:8, pp. 876-882			<input type="checkbox"/>
		MORGAN, JEFFREY R. ET AL., "Rapid Quantitation of Recombinant Retroviruses", Biotechnology Progress, 1994, Vol./Issue No. 10:4, pp. 441-446			<input type="checkbox"/>
		MORITZ, T. ET AL., "Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments", Blood, 1996, Vol./Issue No. 88:3, pp. 855-862			<input type="checkbox"/>
		TRAYCOLL, CM, ET AL., "The 30/35 kD Chymotryptic Fragment of Fibronectin Enhances Retroviral-Mediated Gene Transfer (RMGT) in Chronic Myelogenous Leukemia (CML) CD34+ HLA-DR+ and CD34+ HLA-DR- Bone Marrow Progenitors" Ex Hem. 1995, Vol./Issue No. 22:8, pp. 934			<input type="checkbox"/>

Examiner Signature	/Kelaginamane Hiriyanna/	Date Considered	03/09/2007
-----------------------	--------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.